Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02734615
Title Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

estrogen-receptor positive breast cancer

Therapies

Alpelisib + LSZ 102

LSZ 102 + Ribociclib

LSZ 102

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | DEU | BEL


No variant requirements are available.